Skip to main content Accessibility help
×
Home
  • Print publication year: 2009
  • Online publication date: July 2016

Section 4: - Therapy

References

Abdool Karim SS. Report from the XVI International AIDS Conference. SMART and DART: Intermittent antiretroviral treatment is suboptimal and should be avoided. AIDS Clin Care 2006; 18: 100.
Akerlund B, et al. Effect of N-acetylcysteine (NAC) treatment on HIV-1 infection: a double-blind placebo-controlled trial. Eur J Clin Pharmacol 2004; 50: 457–61.
Abdulle S, et al. CSF neurofilament protein (NFL) – a marker of active HIV-related neurodegeneration. J Neurol 2007; 254: 1026–32.
Andrade AS, et al. A programmable prompting device improves adherence to highly active antiretroviral therapy in HIV-infected subjects with memory impairment. Clin Infect Dis 2005; 41: 875–82.
Antinori A, et al. Biomarkers of HIV-associated neurocognitive disorders. Report from the Conference: HIV infection and the Central Nervous System: Developed and resource limited settings; 2005.
Antinori A, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69(18): 1788–99.
Arendt G, et al. Therapeutic effects of nucleoside analogues on psychomotor slowing in HIV infection. AIDS 2001; 15: 493–500.
Bandaru VVR, et al. Associative and predictive biomarkers of dementia in HIV-1 – infected patients. Neurology 2007; 68: 1481–7.
Baum MD, et al. Selenium and interleukins in persons infected with human immunodeficiency virus type I. J Infect Dis 2000; 182(Suppl 1): S69–73.
Benhamou Y, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 1999; 30: 1054–8.
Benos DJ, et al. Cytokines and HIV envelope glycoprotein gp120 stimulate Na+/H exchange in astrocytes. J Biol Chem 1994; 269: 13811–6.
Berger JR, et al. Cerebrospinal fluid dopamine in HIV-1 infection. AIDS 1994; 8: 67–71.
Bratanich AC, et al. Brain-derived HIV-1 tat sequences from AIDS patients with dementia show increased molecular heterogeneity. J Neurovirol 1998; 4: 387–93.
Brew BJ, et al. Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection. Ann Neurol 1990; 28: 556–60.
Brew BJ. Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex. AIDS 2004; 18(Suppl 1): S75–8.
Brew BJ, et al. Factors in AIDS dementia complex trial design: results and lessons from the abacavir trial. PLoS Clin Trials 2007; 2(3): e13.
Carey CL, et al. Additive deleterious effects of methamphetamine dependence and immunosuppression on neuropsychological functioning in HIV infection. AIDS Behav 2006; 10: 185–90.
Chauhan A, et al. Intracellular human immunodeficiency virus Tat expression in astrocytes promotes astrocyte survival but induces potent neurotoxicity at distant sites via axonal transport. J Biol Chem 2003; 278: 13512–9.
Cherner M, et al. Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis. Neurology 2002; 59: 1563–7.
Childs EA, et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 1999; 52: 607–13.
Ciborowski P, et al. Investigating the human immunodeficiency virus type 1-infected monocyte-derived macrophage secretome. Virology 2007; 363: 198–209.
Cirelli A, et al. Serum selenium concentration and disease progress in patients with HIV infection. Clin Biochem 1991; 24: 211–4.
Clifford DB, et al. A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment. Neurology 2002; 59: 1568–73.
Clifford DB, et al. The neuropsychological and neurological impact of hepatitis C virus co-infection in HIV-infected subjects. AIDS 2005; 19(Suppl 3): S64–S71.
Conant K, et al. Cerebrospinal fluid levels of MMP-2, 7, and 9 are elevated in association with human immunodeficiency virus dementia. Ann Neurol 1999; 46: 391–8.
Costa DC, et al. CBF tomograms with 99mTc-HM-PAO in patients with dementia (Alzheimer type and HIV) and Parkinson’s disease-initial results. J Cereb Blood Flow Metab 1988; 8: S109–15.
Cysique LA, et al. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology 2006a; 66: 1447–50.
Cysique LA, et al. The neuropsychological profile of symptomatic AIDS and ADC patients in the pre-HAART era: A meta-analysis. J Int Neuropsychol Soc 2006b; 12: 368–82.
Dal Pan GJ, et al. Patterns of cerebral atrophy in HIV-1-infected individuals: Results of a quantitative MRI analysis. Neurology 1992; 42: 2125–30.
Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. Safety and tolerability of the antioxidant OPC-14117 in HIV-associated cognitive impairment. Neurology 1997; 49: 142–6.
Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Neurology 1998; 50: 645–51.
Davis HF, et al. Assessing HIV-associated dementia: Modified HIV dementia scale versus the Grooved Pegboard. AIDS Reader 2002; 12: 32–3.
Diop AG, et al. Calbindin D28K-containing neurons and not HSP70-expressing neurons, are more resistant to HIV-1 envelope (gp120) toxicity in cortical cell cultures. J Neurosci Res 1995; 42: 252–8.
Dore GJ, et al. Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 2003; 17: 1539–45.
Dreyer EB, et al. HIV-1 coat protein neurotoxicity prevented by calcium channel antagonists. Science 1990; 248: 364–7.
Egan VG, et al. The Edinburgh cohort of HIV-positive drug users: Current intellectual function is impaired, but not due to early AIDS dementia complex. AIDS 1990; 4: 651–6.
Eletto D, et al. Inhibition of SNAP25 expression by HIV-1 Tat involves the activity of mir-128a. J Cell Physiol 2008; 216: 764–70.
Ellis RJ, et al. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. Ann Neurol 1997; 42: 679–88.
Ellis RJ, et al. Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch Neurol 2002; 59: 923–8.
Ellis R, et al. HIV and antiretroviral therapy in the brain: Neuronal injury and repair. Nat Rev Neurosci 2007; 8: 33–44.
Espinoza L, et al. Characteristics of persons with heterosexually acquired HIV infection, United States 1999–2004. Am J Public Hlth 2007; 97: 1–6.
Everall I, et al. Decreased expression of aMPA receptor messenger RNA and protein in AIDS: A model for HIV-associated neurotoxicity. Nature Med 1995; 1: 1174–8.
Everall IP, et al. Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. Brain Pathol 1999; 9: 209–17.
Ferrando SJ, Batki SL. Substance abuse and HIV infection. New Dir Ment Hlth Serv 2000; 87: 57–67.
Filippi CG, et al. Diffusion tensor imaging of patients with HIV and normal-appearing white matter on MR images of the brain. Am J Neuroradiol 2001; 22: 277–83.
Fox L, et al. Neurodegeneration of somatostatin-immunoreactive neurons in HIV encephalitis. J Neuropathol Exp Neurol 1997; 56(4): 360–8.
Fuchs D, et al. Neopterin concentrations in cerebrospinal fluid and serum of individuals infected with HIV-1. AIDS 1989; 3: 285–8.
Galey D, et al. Differential transcriptional regulation by human immunodeficiency virus type 1 and gp120 in human astrocytes. J Neurovirol 2003; 9: 358–71.
Garden GA, et al. HIV associated neurodegeneration requires p53 in neurons and microglia. FASEB J 2004; 18: 1141–3.
Gartner S. HIV infection and dementia. Science 2000; 287: 602–4.
Gelbard HA. Neuroprotective strategies for HIV-1-associated neurologic disease. Ann NY Acad Sci 1999; 890: 312–13.
Gelbard HA, et al. Platelet-activating factor: A candidate human immunodeficiency virus type 1-induced neurotoxin. J Virol 1994; 68: 4628–35.
Genis P, et al. Cytokines and arachidonic metabolites produced during human immunodeficiency virus (HIV)-infected macrophage–astroglia interactions: Implications for the neuropathogenesis of HIV disease. J Exp Med 1992; 176: 1703–18.
Gibbie T, et al. Depression and neurocognitive performance in individuals with HIV/AIDS: 2-year follow-up. HIV Med 2006; 7: 112–21.
Gonzales E, et al. HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci USA 2002; 99: 13795–800.
Goodkin K, et al. Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial of D-Ala-peptide T-amide for HIV-1 associated cognitive-motor impairment. J NeuroVirol 2006; 12: 178–89.
van Gorp WG, et al. The relationship between employment and neuropsychological impairment in HIV infection. J Int Neuropsychol Soc 1999; 5: 534–9.
Green AJ, et al. Cerebrospinal fluid tau concentrations in HIV infected patients with suspected neurological disease. Sex Transm Infect 2000; 76: 443–6.
Haas D, et al. Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine. AIDS 2000; 14: 1973–8.
Hammoud DA, et al. Imaging glial cell activation with (11C)-R-PK11195 in patients with AIDS. J Neurovirol 2005; 11: 346–55.
Harrich D, Ulich C, Garcia-Martinez LF, Gaynor RB. Tat is required for efficient HIV-1 reverse transcription. EMBO J 1997; 16: 1224–35.
Heaton RK, et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc 2004; 10: 317–31.
Heseltine PNR, et al. Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment. Arch Neurol 1998; 55: 41–51.
Heyes MP, et al. Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann Neurol 1991; 29: 202–9.
Hinkin CH, et al. Cerebral metabolic change in patients with AIDS: Report of a six-month follow-up using positron-emission tomography. J Neuropsychiatry Clin Neurosci 1995; 7: 180–7.
Hinkin CH, et al. Medication adherence among HIV+ adults. Neurology 2002; 59: 1944–50.
Hofman FM, et al. Exogenous tat protein activates central nervous system-derived endothelial cells. J Neuroimmunol 1994; 54: 19–28.
Hudson L, et al. Detection of the human immunodeficiency virus regulatory protein tat in CNS tissues. J Neurovirol 2000; 6: 145–55.
Huntington Study Group. Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington’s disease. Neurology 1998; 50: 1366–73.
Itoh K, et al. Neuronal damage of the substantia nigra in HIV-1 infected brains. Acta Neuropathol (Berl) 2000; 99: 376–84.
Jakobsen J, et al. Cerebral ventricular enlargement relates to neuropsychological measures in unselected AIDS patients. Acta Neurol Scand 1989; 79: 59–62.
Jassoy C, et al. Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes release gamma interferon, tumor necrosis factor-alpha (TNF-alpha) and TNF-beta when they encounter their target antigens. J Virol 1993; 67: 2844–52.
Johnston JB, et al. HIV-1 tat neurotoxicity is prevented by matrix metalloproteinase inhibitors. Ann Neurol 2001; 49: 230–41.
Jones MV, et al. Immunolocalization of HIV envelope gp120 in HIV encephalitis with dementia. AIDS 2000; 14: 2709–13.
Kandanearatchi A, et al. Assessing the efficacy of highly active antiretroviral therapy in the brain. Brain Pathol 2003; 13: 104–10.
Kawamata T, et al. Antioxidant, OPC-14117, attenuates edema formation and behavioral deficits following cortical contusion in rats. Acta Neurochir Suppl 1997; 70: 191–3.
Kelly GS. Clinical applications of N-acetylcysteine. Alt Med Rev 1998; 3: 114–27.
Kieburtz KD, et al. Excitotoxicity and dopaminergic dysfunction in the acquired immunodeficiency syndrome dementia complex. Therapeutic implications. Arch Neurol 1991; 48: 1281–4.
Kim BO, et al. Neuropathologies in transgenic mice expressing human immunodeficiency virus type 1 Tat protein under the regulation of the astrocyte-specific glial fibrillary acidic protein promoter and doxycycline. Am J Pathol 2003; 162: 1693–3403.
Koh KK, et al. Non-lipid effects of statin on hypercholesterolemic patients established to have coronary artery disease who remained hypercholesterolemic while eating a step-II diet. Coron Artery Dis 2001; 12: 305–11.
Koutsilieri E, et al. Monoamine oxidase inhibition and CNS immunodeficiency infection. NeuroToxicology 2004; 25: 267–270.
Lacomblez L, et al. Tolerance of riluzole in a phase IIIb clinical trial. Therapie 2002; 57: 65–71.
Langford D, et al. Patterns of selective neuronal damage in methamphetamine-user AIDS patients. J Acquir Immune Defic Syndr 2003; 34: 467–74.
Langford D, et al. Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients. J Neurovirol 2006; 12:100–7.
Lanier ER, et al. HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir. AIDS 2001; 15: 747–51.
Lipton SA, et al. Synergistic effects of HIV coat protein and NMDA receptor-mediated neurotoxicity. Neuron 1991; 7: 111–8.
Maggirwar SB, et al. HIV-1 tat-mediated activation of glycogen synthase kinase-3B contributes to tat-mediated neurotoxicity. J Neurochem 1999; 73: 578–86.
Magnuson D, et al. Human immunodeficiency virus type 1 Tat activates non-N-methyl-d-aspartate excitatory amino acid receptors and causes neurotoxicity. Ann Neurol 1995; 37: 373–80.
Maragos WF, et al. Neuronal injury in hippocampus with human immunodeficiency virus transactivating protein, TAT. Neuroscience 2003; 117: 43–53.
Marcotte TD, et al. A multimodal assessment of driving performance in HIV infection. Neurology 2004; 26 : 1417–22.
Marra C, et al. ACTG 736:CSF HIV-1 and cognitive function in individuals receiving potent ART. 13th CROI, session 70, abstract no. 361; 2006.
Martin C, et al. Indinavir-based treatment of HIV-1 infected patients: Efficacy in the central nervous system. AIDS 1999; 13: 1227–32.
Masliah E, et al. Spectrum of human immunodeficiency virus-associated neocortical damage. Ann Neurol 1992; 32: 321–9.
Mayeux R, et al. Mortality risks in gay men with human immunodeficiency virus infection and cognitive impairment. Neurology 1993; 43: 176–82.
McArthur JC, et al. The diagnostic utility of elevation in cerebrospinal fluid beta 2-microglobulin in HIV-1 dementia. Multicenter AIDS Cohort Study. Neurology 1992; 42: 1707–12.
McArthur JC, et al. Dementia in AIDS patients: Incidence and risk factors. Neurology 1993; 43: 2245–52.
McArthur JC, et al. Human immunodeficiency virus-associated dementia: An evolving disease. J NeuroVirol 2003; 9: 205–21.
McArthur JC, et al. Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy. Arch Neurol 2004; 61: 1687–96.
McArthur JC, et al. Neurological complications of HIV infection. Lancet Neurol 2005; 4: 543–55.
Merrill J, et al. Induction of interleukin-1 and tumor necrosis factor alpha in brain cultures by human immunodeficiency virus type 1. J Virol 1992; 66: 2217–25.
Miller EN, et al. Neuropsychological performance in HIV-1-infected homosexual men: MACS. Neurology 1990; 40: 197–203.
Miller RF, et al. Detection of 14–3–3 brain protein in cerebrospinal fluid of HIV infected patients. Sex Transm Infect 2000; 76: 408.
Mintz M, et al. Neurology 1996; 47: 1583–5.
Monteiro de Almeida S, et al. Dynamics of monocyte chemoattractant protein type one (MCP-1) and HIV viral load in human cerebrospinal fluid and plasma. J Neuroimmunol 2005; 169: 144–52.
Moore DJ, et al. Cortical and subcortical neurodegeneration is associated with HIV neurocognitive impairment. AIDS 2006; 20: 879–87.
Morgello S, et al. Effects of hepatic function and hepatitis C virus on the nervous system assessment of advanced-stage HIV-infected individuals. AIDS 2005; 19(Suppl 3): S116–22.
Nath A, et al. Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: Protection by memantine. Ann Neurol 2000; 47: 186–94.
Nath A, et al. Molecular basis for interactions of HIV and drugs of abuse. J AIDS 2002; 31: S62–9.
Navia BA, Price RW. The acquired immunodeficiency syndrome dementia complex as the presenting or sole manifestation of human immunodeficiency virus infection. Arch Neurol 1987; 44: 65–9.
Navia BA, et al. The AIDS dementia complex: Clinical features. Ann Neurol 1986; 19: 517–24.
Navia BA, et al. A phase I/II trial of nimodipine for HIV-related neurologic complications. Neurology 1998; 51: 221–8.
Neuenburg JK, et al. HIV-related neuropathology, 1985 to 1999: Rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 31: 171–7.
Oshiro Y, et al. Novel cerebroprotective agents with central nervous system stimulating activity. 2. Synthesis and pharmacology of the 1-(acylamino)-7-hydroxyindan derivatives. J Med Chem 1991; 34: 2014–23.
Pascal S, et al. Metabolic asymmetries in asymptomatic HIV-1 seropositive subjects: Relationship to disease onset and MRI findings. J Nucl Med 1991; 32: 1725–9.
Patton HK, et al. Gp120-induced alterations of human astrocyte function: Na+/H+ exchange, K+ conductance and glutamate flux. Am J Physiol Cell Physiol 2000; 279: C700–08.
Pemberton LA, Brew BJ. Cerebrospinal fluid S-100beta and its relationship with AIDS dementia complex. J Clin Virol 2001; 22: 249–53.
Pert CB, et al. Octapeptides deduced from the neuropeptide receptor-like pattern of antigen T4 in brain potently inhibit human immunodeficiency virus receptor binding and T-cell infectivity. Proc Nat Acad Sci 1986; 83: 9254–8.
Price RW, et al. Neurological outcomes in late HIV infection: Adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS 1999; 13: 1677–85.
Quasney MW, et al. Increased frequency of the tumor necrosis factor-alpha-308 A allele in adults with human immunodeficiency virus dementia. Ann Neurol 2001; 50: 157–62.
Ragin AB, et al. Disease burden in HIV-associated cognitive impairment: A study of whole-brain imaging measures. Neurology 2004; 63: 2293–7.
Ragin AB, et al. Diffusion tensor imaging of subcortical brain injury in patients infected with human immunodeficiency virus. J Neurovirol 2005; 11: 292–8.
Ranki A, et al. Abundant expression of HIV Nef and Rev proteins in brain astrocytes in vivo is associated with dementia. AIDS 1995; 9: 1001–8.
Rapp SR, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women’s Health Initiative Memory Study: A randomized controlled trial. J Am Med Assoc 2003; 289: 2663–72.
Resnick L, et al. Early penetration of the blood-brain-barrier by HIV. Neurology 1988; 38: 9–14.
Reynolds IJ, Aizeman E. Pentamidine is an N-methyl-D-aspartate receptor antagonist and is neuroprotective in vitro. J Neurosci 1992; 12: 970–5.
Richard A, et al. Interference of HIV-1 Nef in the sphingomyelin transduction pathway activated by tumour necrosis factor-alpha in human glial cells. AIDS 1997; 11: F1–7.
Riedel DJ, et al. Therapy insight: CNS manifestations of HIV-associated immune reconstitution inflammatory syndrome. Nat Clin Pract Neurol 2006; 2: 557–65.
Rippeth JD, et al. Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. JINS 2004; 10: 1–14.
Robert-Guroff M, et al. Stucture and expression of tat-, rev- and nef-specific transcripts of human immunodeficiency virus type 1 in infected lymphocytes and macrophages. J Virol 1990; 64: 3391–8.
Robinson B, et al. Modulation of human immunodeficiency virus infection by anticonvulsant drugs. J Neurovirol 2006; 12: 1–4.
Rosen CA, et al. Intragenic cis-acting art gene-responsive sequences of the human immunodeficiency virus. Proc Natl Acad Sci 1988; 85: 2071–5.
Rosenberg GA, Navratil M. Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat. Neurology 1997; 48: 921–6.
Ruben S, et al. Structural and functional characterization of human immunodeficiency virus tat protein. J Virol 1989; 63: 1–8.
Rumbaugh JA, Nath A. Developments in HIV neuropathogenesis. Curr Pharm Des 2006; 12: 1023–44.
Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol 2002; 8: 115–21.
Sacktor N, et al. A comparison of cerebral SPECT abnormalities in HIV-positive homosexual men with and without cognitive impairment. Arch Neurol 1995a; 52: 1170–3.
Sacktor N, et al. Cerebral single-photon emission computed tomography abnormalities in human immunodeficiency virus type 1-infected gay men without cognitive impairment. Arch Neurol 1995b; 52: 607–11.
Sacktor N, et al. Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study. Neurology 2000; 54: 233–5.
Sacktor N, et al. HIV-associated neurologic disease incidence changes: Multicenter Aids Cohort Study, 1990–1998. Neurology 2001; 56: 257–60.
Sacktor N, et al. Response to systemic HIV viral load suppression correlates with psychomotor speed performance. Neurology 2003; 61: 567–9.
Sacktor NC, et al. The International HIV Dementia Scale: A new rapid screening test for HIV dementia. AIDS 2005a; 19: 1367–74.
Sacktor N, et al. A multicenter study of two magnetic resonance spectroscopy techniques in individuals with HIV dementia. J Magn Reson Imaging 2005b; 21: 325–33.
Sacktor N, et al. Antiretroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa. Neurology 2006; 67: 311–14.
Sadek JR, et al. Retrograde amnesia in dementia: Comparison of HIV-associated dementia, Alzheimer’s disease, and Huntington’s disease. Neuropsychology 2004; 18: 692–9.
Saito Y, et al. Overexpression of nef as a marker for restricted HIV-1 infection of astrocytes in postmortem pediatric central nervous tissues. Neurology 1994; 44: 474–81.
Sardar AM, et al. Dopamine deficits in the brain: The neurochemical basis of parkinsonian symptoms in AIDS. Neuroreport 1996; 7: 910–12.
Schifitto G, et al. Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment. Neurology 1999; 53: 391–6.
Schifitto G, et al. Clinical trials in HIV-associated cognitive impairment: Cognitive and functional outcomes. Neurology 2001; 56: 415–8.
Schifitto G, et al. Valproic acid adjunctive therapy for HIV-associated cognitive impairment: A first report. Neurology 2006; 66: 919–21.
Selnes OA, et al. HIV-1 infection: No evidence of cognitive decline during the asymptomatic stages. The Multicenter AIDS Cohort Study. Neurology 1990; 40: 204–8.
Sevigny JJ, et al. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology 2004; 63: 2084–90.
Shelburne SA, et al. Immune reconstitution inflammatory syndrome. Medicine 2002; 81: 213–27.
Shelburne SA, et al. Immune reconstitution inflammatory syndrome: More answers, more questions. J Antimicrob Chemother 2006; 57: 167–70.
Sidtis JJ, et al. Zidovudine treatment of the AIDS dementia complex: Results of a placebo-controlled trial. Ann Neurol 1993; 33: 343–9.
Stauber RH, Pavlakis GN. Intracellular trafficking and interactions of the HIV-1 Tat protein. Virology 1998; 252: 126–36.
Stephans SE, Yamamoto BK. Methamphetamine-induced neurotoxicity: Roles for glutamate and dopamine efflux. Synapse 1994; 17: 203–9.
Stout JC, et al. Progressive cerebral volume loss in human immunodeficiency virus infection: A longitudinal volumetric magnetic resonance imaging study. HIV neurobehavioral Research Center Group. Arch Neurol 1998; 55: 161–8.
Su ZZ, et al. Identification of gene products suppressed by human immunodeficiency virus type 1 infection or gp120 exposure of primary human astrocytes by rapid subtraction hybridization. J NeuroVirol 2003; 9: 372–89.
Sulkowski MS, et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. J Am Med Assoc 2000; 283: 74–80.
Sung JH, et al. Protective effect of glutathione in HIV-1 lytic peptide 1-induced cell death in human neuronal cells. J Neurovirol 2001; 7: 454–65.
Tarasow E, et al. Cerebral MR spectroscopy in neurologically asymptomatic HIV-infected patients. Acta Radiol 2003; 44: 206–12.
Tarasow E, et al. Antiretroviral therapy and its influence on the stage of brain damage in patients with HIV-1H MRS evaluation. Med Sci Monit 2004; 10(Suppl 3): 101–6.
Tardieu M, et al. Human immunodeficiency virus type 1-infected monocytic cells can destroy human neuronal cells after cell-to-cell adhesion. Ann Neurol 1992; 32: 11–7.
Tatsch K, et al. Functional and morphological findings in early and advanced stages of HIV infection: A comparison of 99mTc-HMPAO SPECT with CT and MRI studies. Nuklearmedizin 1990; 29: 252–8.
Taylor MJ, et al. MR spectroscopy in HIV and stimulant dependence. J Int Neuropsychol Soc 2000; 6: 83–5.
Thompson PM, et al. Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4+ T lymphocyte decline. Proc Natl Acad Sci USA 2005; 102: 15647–52.
Tomlinson GS, et al. Upregulation of microglia in drug users with and without pre-symptomatic HIV infection. Neuropathol Appl Neurobiol 1999; 25: 369–79.
Tornatore C, et al. HIV-1 infection of subcortical astrocytes in the pediatric central nervous system. Neurology 1994; 44: 481–7.
Tracey I, et al. Increased cerebral blood volume in HIV-positive patients detected by functional MRI. Neurology 1998; 50(6): 1821–6.
Tucker KA, et al. Neuroimaging in human immunodeficiency virus infection. J Neuroimmunol 2004; 157: 153–62.
Turchan J, et al. Neuroprotective therapy for HIV dementia. Cur HIV Res 2003; 1: 373–83.
Valle LD, et al. Detection of HIV-1 Tat and JCV capsid protein, VP1, in AIDS brain with progressive multifocal leukoencephalopathy. J Neurovirol 2000; 6: 221–8.
Venkataramana A, et al. Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients. Neurology 2006; 67: 383–8.
Vignoli AL, et al. Neuronal glycolytic pathway impairment induced by HIV envelope glycoprotein gp120. Mol Cell Biochem 2000; 215: 73–80.
Wachtmann LM, et al. Platelet decline: An early predictive hematologic marker of simian immunodeficiency virus central nervous system disease. J Neurovirol 2006; 12: 25–33.
Wendel KA, McArthur JC. Acute meningoencephalitis in chronic human immunodeficiency virus (HIV) infection: Putative central nervous system escape of HIV replication. Clin Infect Dis 2003; 37: 1107–11.
Wesselingh SL, et al. Intracerebral cytokine messenger RNA expression in acquired immunodeficiency syndrome dementia. Ann Neurol 1993; 33: 576–82.
Wiley CA, et al. Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci 1986; 83: 7089–93.
Wilkie FL, et al. Mild cognitive impairment and risk of mortality in HIV-1 infection. J Neuropsychiatry Clin Neurosci 1998; 10: 125–32.
Wilson ME, et al. Immune modulation by estrogens: role in CNS HIV-1 infection. Endocrine 2006; 29: 289–97.
Wilt SG, et al. In vitro evidence for a dual role of tumor necrosis factor-alpha in human immunodeficiency virus type 1 encephalopathy. Ann Neurol 1995; 37: 381–94.
Wojna V, et al. Prevalence of human immunodeficiency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairment. J Neurovirol 2006; 12: 356–64.
Wojna V, Nath A. Challenges to the diagnosis and management of HIV dementia. AIDS Read 2007; 16: 615–16, 621–4, 629–32.
Wojtowicz-Praga S. Clinical potential of matrix metalloprotease inhibitors. Drugs R D 1999; 1: 117–29.
Wong MH, et al. Frequency of and risk factors for HIV dementia in an HIV clinic in sub-Saharan Africa. Neurology 2007; 68: 350–5.
Woody GE, et al. Non-injection substance use correlates with risky sex among men having sex with men: Data from HIVNET. Drug Alcohol Depend 1999; 53: 197–205.
Wright E, et al. Neurologic disorders are prevalent in HIV-positive outpatients in the Asia–Pacific region. 2008; 71: 50–6.
Wu YC, et al. AIDS dementia complex in China. J Clin Neurosci 2007; 14: 8–11.
Yi Y, et al. Chemokine receptor utilization and macrophage signaling by human immunodeficiency virus type 1 gp120: Implications for neuropathogenesis. J Neurovirol 2004; 10(Suppl 1): 91–6.
Yuen AW. Lamotrigine: A review of antiepileptic efficacy. Epilepsia 1994; 35(Suppl 5): S33–6.
Zink MC, et al. Neuroprotective and anti-human immunodeficiency virus activity of minocycline. J Am Med Assoc 2005; 293: 2003–11.

References

Aderem A, Ulevitch R. Toll-like receptors in the induction of the innate immune response. Nature 2000; 406: 782–7.
Aguilar-Rebolledo F, et al. Interleukin levels in cerebrospinal fluid from children with neurocysticercosis. Am J Trop Med Hyg 2001; 64: 35–40.
Aiba H, et al. Predictive value of serum interleukin-6 level in influenza virus-associated encephalopathy. Neurology 2001; 57: 295–9.
Akira S. The role of IL-18 in innate immunity. Curr Opin Immunol 2000; 12: 59–63.
Akwa Y, et al. Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J Immunol 1998; 161: 5016–26.
Albrecht H, et al. Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy. AIDS 1998; 12: 1149–54.
Aloisi F, et al. Glia-T cell dialogue. J Neuroimmunol 2000; 107: 111–7.
Al-Qaoud KM, Abdul-Hafez SK. The induction of T helper type 1 response by cytokine gene transfection protects mice against secondary hydatidosis. Parasitol Res 2008; 102: 1151–5.
Altavilla D, et al. IRFI 042, a novel dual vitamin E-like antioxidant, inhibits activation of nuclear factor-kappa B and reduces the inflammatory response in myocardial ischaemia-reperfusion injury. Cardiovasc Res 2000; 47: 515–28.
Amirayan-Chevillard N, et al. Impact of highly active anti-retroviral therapy (HAART) on cytokine production and monocyte subsets in HIV-infected patients. Clin Exper Immunol 2000; 120: 107–12.
Anderson JF, Rahal J. Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro. Emerg Infect Dis 2002; 8: 107–8.
Andersson J, et al. Interferon gamma (IFN-gamma) deficiency in generalized Epstein–Barr virus infection with interstitial lymphoid and granulomatous pneumonia, focal cerebral lesions, and genital ulcers: Remission following IFN-gamma substitution therapy. Clin Infect Dis 1999; 28: 1036–42.
Angel JB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of recombinant human interleukin-10 in HIV-infected subjects. Aids 2000; 14: 2503–8.
Anguita J, et al. Effect of anti-interleukin 12 treatment on murine Lyme borreliosis. J Clin Invest 1996; 97: 1028–34.
Angulo I, Fresno M. Cytokines in the pathogenesis of and protection against malaria. Clin Diagnost Lab Immunol 1145; 9: 1145–52.
Anlar B, et al. Cimetidine as an immunomodulator in subacute sclerosing panencephalitis: A double blind, placebo-controlled study. Pediatr Infect Dis J 1993; 12: 578–81.
Anlar B, et al. Long-term follow-up of patients with subacute sclerosing panencephalitis treated with intraventricular alpha-interferon. Neurology 1997; 48: 526–8.
Anlar B, et al. Beta-interferon plus inosiplex in the treatment of subacute sclerosing panencephalitis. J Child Neurol 1998; 13: 557–9.
Anlar B, et al. Retrospective evaluation of interferon-beta treatment in subacute sclerosing panencephalitis. Clin Ther 2004; 26: 1890–4.
Aparicio AG, et al. Report of an additional case of anti-tumor necrosis factor therapy and Listeria monocytogenes infection: comment on the letter by Gluck et al. Arthrit Rheumat 2003; 48: 1764–5.
Araujo FG, Remington JS. Synergistic activity of azithromycin and gamma interferon in murine toxoplasmosis. Antimicrob Agents Chemother 1991; 35: 1672–3.
Araujo FG, et al. Treatment with interleukin 12 in combination with Atovaquone or Clindamycin significantly increases survival of mice with acute toxoplasmosis. Antimicrob Agents Chemother 1997; 41: 188–90.
Aravalli RN, et al. Cutting edge: TLR2-mediated pro-inflammatory cytokine and chemokine production by microglial cells in response to herpes simplex virus. J Immunol 2005; 175: 4189–93.
Archin NM, et al. Delayed spread and reduction in virus titer after anterior chamber inoculation of a recombinant of HSV-1 expressing IL-16. Invest Ophthalmol Vis Sci 2003; 44: 3066–76.
Asensio VC, et al. Chemokines and the inflammatory response to viral infection in the central nervous system with a focus on lymphocytic choriomeningitis virus. J Neurovirol 1999; 5: 65–75.
Aubouy A, et al. Plasma and in vitro levels of cytokines during and after a Plasmodium falciparum malaria attack in Gabon. Acta Tropica 2002; 83: 195–203.
Aurelius E, et al. Cytokines and other markers of intrathecal immune response in patients with herpes simplex encephalitis. J Infect Dis 1994; 170: 678–81.
Aydin OF, et al. Combined treatment with subcutaneous interferon-alpha, oral isoprinosine, and lamivudine for subacute sclerosing panencephalitis. J Child Neurol 2003; 18: 104–8.
Balan V, et al. A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy. Antivir Ther 2006; 11: 35–45.
Beaman M. Cytokine therapy of infectious diseases. In: Schwartz M, Remington J (Eds.). Current Topics in Infectious Diseases. Cambridge, MA: Blackwell Scientific Publications, 1994; 14: 228–51.
Beaman MH, et al. Enhancement of intracellular replication of Toxoplasma gondii by interleukin-6: Interactions with interferon-γ and tumor necrosis factor-α. J Immunol 1994; 153: 4583–7.
Beland JL, et al. Recombinant CD40L treatment protects allogeneic murine bone marrow transplant recipients from death caused by herpes simplex virus-1 infection. Blood 1998; 92: 4472–8.
Benedetto N, et al. Effect of rIFN-gamma and IL-2 treatments in mouse and nude rat infections with Toxoplasma gondii. Eur Cytokine Netw 1991; 2: 107–14.
Benito C, et al. A glial endogenous cannabinoid system is upregulated in the brains of macaques with simian immunodeficiency virus-induced encephalitis. J Neurosci 2005; 25: 2530–6.
Bernardo A, Minghetti L. PPAR-gamma agonists as regulators of microglial activation and brain inflammation. Curr Pharm Des 2006; 12: 93–109.
Binder GK, Griffin DE. Interferon-gamma-mediated site-specific clearance of alphavirus from CNS neurons. Science 2001; 293: 303–6.
Borish LC, et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001; 107: 963–70.
Bosticardo M, et al. Retroviral-mediated gene transfer restores IL-12 and IL-23 signaling pathways in T cells from IL-12 receptor beta1-deficient patients. Mol Ther 2004; 9: 895–901.
Briscoe H, et al. A novel tumor necrosis factor (TNF) mimetic peptide prevents recrudescence of Mycobacterium bovis bacillus Calmette–Guerin (BCG) infection in CD4(+) T cell-depleted mice. J Leukocyte Biol 2000; 68: 538–44.
Brooks TJ, Philpotts R. Interferon-alpha protects mice against lethal infection with St Louis encephalitis virus delivered by the aerosol and subcutaneous routes. Antiviral Res 1999; 41: 57–64.
Buckwold VE, et al. Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses. Antiviral Res 2007; 73: 118–25.
Burighel N, et al. Differential dynamics of Epstein–Barr virus in individuals infected with human immunodeficiency virus-1 receiving intermittent interleukin-2 and antiretroviral therapy. Haematologica 2006; 91: 244–7.
Burroughs MH, et al. Effect of thalidomide on the inflammatory response in cerebrospinal fluid in experimental bacterial meningitis. Microb Pathogen 1995; 19: 245–55.
Caksen H, et al. Onset of generalized seizures after intrathecal interferon therapy of SSPE. Pediatr Neurol 2003; 29: 78–9.
Carr DJ. Increased levels of IFN-gamma in the trigeminal ganglion correlate with protection against HSV-1-induced encephalitis following subcutaneous administration with androstenediol. J Neuroimmunol 1998; 89: 160–7.
Carrier EJ, et al. Endocannabinoids in neuroimmunology and stress. Curr Drug Targets CNS Neurol Disord 2005; 4: 657–65.
Chang H, et al. Role of tumour necrosis factor in chronic murine Toxoplasma gondii encephalitis. Immun Infect Dis 1992; 2: 61–8.
Chan-Tack KM, Forrest G. Failure of interferon alpha-2b in a patient with West Nile virus meningoencephalitis and acute flaccid paralysis. Scand J Infect Dis 2005; 37: 944–6.
Chao CC, et al. Human microglial cell defense against Toxoplasma gondii. The role of cytokines. J Immunol 1994; 152: 1246–52.
Cianchetti C, et al. Toxic effect of intraventricular interferon-alpha in subacute sclerosing panencephalitis. Ital J Neurol Sci 1994; 15: 153–5.
Coltri C, et al. Therapeutic administration of KM+ lectin protects mice against Paracoccidiodes brasiliensis infection via interleukin-12 production in a toll-like receptor 2-dependant mechanism. Am J Pathol 2008; 173: 423–32.
Combe CL, et al. Lack of IL-15 results in the suboptimal priming of CD4+ T cell response against an intracellular parasite. Proc Natl Acad Sci 2006; 103: 6635–40.
Condos R, et al. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet 1997; 349: 1513–15.
Constantinescu CS, et al. Astrocytes as antigen-presenting cells: Expression of IL-12/IL-23. J Neurochem 2005; 95: 331–40.
Craiu A, et al. An IL-2/Ig fusion protein influences CD4(+) T lymphocytes in naive and simian immunodeficiency virus-infected rhesus monkeys. AIDS Res Human Retrovir 2001; 17: 873–86.
Croce M, et al. Sequential immunogene therapy with interleukin-12- and interleukin-15-engineered neuroblastoma cells cures metastatic disease in syngeneic mice. Clin Cancer Res 2005; 11: 735–42.
Cruikshank WW, et al. Interleukin-16 [Review]. J Leukocyte Biol 2000; 67: 757–66.
Cui B, Carr DJ. A plasmid construct encoding murine interferon beta antagonizes the replication of herpes simplex virus type I in vitro and in vivo. J Neuroimmunol 2000; 108: 92–102.
Czuprynski CJ, et al. Effects of murine recombinant interleukin 1 alpha on the host response to bacterial infection. J Immunol 1994; 140: 962–8.
D’Aversa TG, et al. CD40–CD40L interactions induce chemokine expression by human microglia: Implications for human immunodeficiency virus encephalitis and multiple sclerosis. Am J Pathol 2002; 160: 559–67.
Davis RL, et al. Effects of mechanistically distinct NF-kappaB inhibitors on glial inducible nitric-oxide synthase expression. Nitric Oxide 2005; 12: 200–9.
de Gans J, et al. Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002; 347: 1549–56.
de Lalla F, et al. Safety and efficacy of recombinant granulocyte colony-stimulating factor as an adjunctive therapy for Streptococcus pneumoniae meningitis in non-neutropenic adult patients: A pilot study. J Antimicrob Chemother 2000; 46: 843–6.
Deckert M, et al. Endogenous interleukin-10 is required for prevention of a hyperinflammatory intracerebral immune response in Listeria monocytogenes meningoencephalitis. Infect Immun 2001; 69: 4561–71.
Dietrich JB. The adhesion molecule ICAM-1 and its regulation in relation with the blood–brain barrier. J Neuroimmunol 2002; 128: 58–68.
Dinarello CA. Proinflammatory cytokines. Chest 2000; 118: 503–8.
Dix RD, Cousins SW. Interleukin-2 immunotherapy of murine cytomegalovirus retinitis during MAIDS correlates with increased Intraocular CD8+ T-cell infiltration. Ophthalm Res 2003; 35: 154–9.
Dix RD, et al. Systemic cytokine immunotherapy for experimental cytomegalovirus retinitis in mice with retrovirus-induced immunodeficiency. Invest Ophthalmol Vis Sci 1997; 38: 1411–17.
Donnely S, et al. Helminth 2-Cys peroxiredoxin drives Th2 responses through a mechansim involving alternatively activated macrophages. FASEB J 2008; 22 : 4022–32.
Dorr J, et al. Tumor-necrosis-factor-related apoptosis-inducing-ligand (TRAIL)-mediated death of neurons in living human brain tissue is inhibited by flupirtine-maleate. J Neuroimmunol 2005; 167: 204–9.
Duan X, et al. Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases. Cancer 2006; 106: 1382–8.
Eisenbeis CF, et al. Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: Evidence for modulation of interferon signalling pathways by interleukin-12. J Clin Oncol 2005; 23: 8835–44.
Elisabetta V, et al. The endogenous estrogen status regulates microglia reactivity in animal models of neuroinflammation. Endocrinology 2006; 147: 2263–72.
Faber M, et al. Overexpression of tumor necrosis factor alpha by a recombinant rabies virus attenuates replication in neurons and prevents lethal infection in mice. J Virol 2005; 79: 15405–16.
Felderhoff-Mueser U, et al. IL-18: A key player in neuroinflammation and neurodegeneration? Trends Neurosci 2005; 28: 487–93.
Fernandez-Botran R. Soluble cytokine receptors: Their role in immunoregulation. FASEB J 1991; 5: 2567–74.
Fieschi C, et al. High risk of infectious disease caused by salmonellae and mycobacteria infections in patients with Crohn disease treated with anti-interleukin-12 antibody. Clin Infect Dis 2005; 40: 1381.
Filipe-Santos O, et al. Inborn errors of IL-12/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical features. Semin Immunol 2006; 18: 347–61.
Finke D, et al. Gamma interferon is a major mediator of antiviral defense in experimental measles virus-induced encephalitis. J Virol 1995; 69: 5469–74.
Finsterer J, et al. Multifocal leukoencephalopathy and polyneuropathy after 18 years on interferon alpha. Leuk Lymphoma 2005; 46: 277–80.
Flesch IE, Kaufmann SH. Role of cytokines in tuberculosis [Review]. Immunobiology 1993; 189: 316–39.
Flesch IE, et al. Effects of IL-13 on murine listeriosis. Int Immunol 1997; 9(4): 467–74.
Fukuda T, et al. Treatment with Y-40138, a multiple cytokine production modulator, inhibits lipopolysaccharide- or tumour necrosis factor-alpha-induced production of pro-inflammatory cytokines and augments interleukin-10. J Pharm Pharmacol 2005; 57: 1461–6.
Gadoth N, et al. The interferon system in subacute sclerosing panencephalitis and its response to isoprinosine. Brain Dev 1989; 11: 308–12.
Gallin JI, et al. Interferon-gamma in the management of infectious diseases. Ann Intern Med 1995; 124: 216–24.
Garg R. Subacute sclerosing panencephalitis. Postgrad Med J 2002; 78: 63–70.
Gascon G, et al. Randomized treatment study of inosiplex versus combined inosiplex and intraventricular interferon-alpha in subacute sclerosing panencephalitis (SSPE): International multicenter study. J Child Neurol 2003; 18: 819–27.
Gately MK, Mulqueen MJ. Interleukin-12 – Potential clinical applications in the treatment and prevention of infectious diseases. Drugs 1996; 52(Suppl 2): 18–25.
Gazzinelli R, et al. Interleukin-12 is required for the T-lymphocyte-independent induction of interferon-g by an intracellular parasite and induces resistance in T-cell-deficient hosts. Proc Natl Acad Sci 1993; 90: 6115–19.
Gazzinelli RT, et al. In the absence of endogenous IL-LO, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4(+) T cells and accompanied by overproduction of IL-12, IFN-gamma, and TNF-alpha. J Immunol 1996; 157(2): 798–805.
Geschwind MD, et al. The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS. J Neurovirol 2001; 7: 353–7.
Ghiasi H, et al. Overexpression of interleukin-2 by a recombinant herpes simplex virus type 1 attenuates pathogenicity and enhances antiviral immunity. J Virol 2002; 76: 9069–78.
Giosue S, et al. Effects of aerosolized interferon-alpha in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 1998; 158: 1156–62.
Giosue S, et al. Aerosolized interferon-alpha treatment in patients with multi-drug-resistant pulmonary tuberculosis. Eur Cytok Network 2000; 11: 99–104.
Gokcil Z, et al. Alpha-interferon and isoprinosine in adult-onset subacute sclerosing panencephalitis. J Neurol Sci 1999; 162: 62–4.
Gosselin J, et al. Interleukin-15 as an activator of natural killer cell-mediated antiviral response. Blood 1999; 94: 4210–19.
Grau G, Modlin R. Immune mechanisms in bacterial and parasitic diseases: Protective immunity versus pathology. Curr Opin Immunol 1991; 3: 480–5.
Greenwood J, et al. Lymphocyte migration into the central nervous system: Implication of ICAM-1 signalling at the blood–brain barrier. Vascul Pharmacol 2002; 38: 315–22.
Griffin D. Immune responses during measles virus infection. Curr Top Microbiol Immunol 1995; 191: 117–34.
Griffin DE. Immune responses to RNA-virus infections of the CNS [Review]. Nature Rev Immunol 2003; 3: 493–502.
Gringeri A, et al. Active anti-interferon-alpha immunization: A European–Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1-infected patients (the EURIS study). J AIDS Human Retrovirol 1999; 20: 358–70.
Haddad FS, Risk W. Isoprinosine treatment in 18 patients with subacute sclerosing panencephalitis: A controlled study. Ann Neurol 1980; 7: 185–8.
Hammerbeck DM, et al. Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats. Antiviral Res 2006; 73: 1–11.
Hanada N, et al. Combined effects of acyclovir and human interferon-alpha on herpes simplex virus replication in cultured neural cells. J Med Virol 1989; 29: 7–12.
Hanisch UK, et al. Mouse brain microglia express interleukin-15 and its multimeric receptor complex functionally coupled to Janus kinase activity. J Biol Chem 1997; 272: 288853–60.
Happel KI, et al. Pulmonary interleukin-23 gene delivery increases local T-cell immunity and controls growth of Mycobacterium tuberculosis in the lungs. Infect Immun 2005; 73: 5782–8.
Happel KI, et al. Cutting edge: Roles of toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection. J Immunol 2003; 170: 4432–6.
Hara S, et al. Combination therapy with intraventricular interferon-alpha and ribavirin for subacute sclerosing panencephalitis and monitoring measles virus RNA by quantitative PCR assay. Brain Dev 2003; 25: 367–9.
Hart OM, et al. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production. J Immunol 2005; 175: 1636–42.
Hasselblatt M, et al. The brain erythropoietin system and its potential for therapeutic exploitation in brain disease. J Neurosurg Anesthesiol 2006; 18: 132–8.
Heide W, et al. Failure of cytarabine/interferon therapy in progressive multifocal leukoencephalopathy. Ann Neurol 1995; 37: 412–13.
Heimann DM, Schwarzentruber D. Gastrointestinal perforations associated with interleukin-2 administration. J Immunother 2004; 27: 254–8.
Heneka MT, et al. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1–42 levels in APPV717I transgenic mice. Brain 2005; 128: 1442–53.
Ho M, et al. Endogenous interleukin-10 modulates proinflammatory response in Plasmodium falciparum malaria. J Infect Dis 1998; 178: 520–5.
Holland SM. Cytokine therapy of mycobacterial infections. Adv Intern Med 2000a; 45: 431–52.
Holland SM. Treatment of infections in the patient with Mendelian susceptibility to mycobacterial infection. Microbes Infect 2000b; 2: 1579–90.
Hosoya M, et al. High-dose intravenous ribavirin therapy for subacute sclerosing panencephalitis. Antimicrob Agents Chemother 2001; 45: 943–5.
Huang SS, et al. Survival prolongation in HIV-associated progressive multifocal leukoencephalopathy treated with alpha-interferon: An observational study. J Neurovirol 1998; 4: 324–32.
Hussey GD, Klein M. A randomized, controlled trial of vitamin A in children with severe measles. N Engl J Med 1990; 323: 160–4.
Ifergan I, et al. Statins reduce human blood–brain barrier permeability and restrict leukocyte migration: Relevance to multiple sclerosis. Ann Neurol 2006; 60: 45–55.
Ikeda M, et al. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 2006; 44: 117–25.
Inoue H, et al. Modulation of the human interleukin-12p40 response by a triazole antifungal derivative, itraconazole. Scand J Infect Dis 2004; 36: 607–9.
Jackson AC, et al. Expression of Toll-like receptor 3 in the human cerebellar cortex in rabies, herpes simplex encephalitis, and other neurological diseases. J Neurovirol 2006; 12: 229–34.
Jacobson MA, et al. Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12. Vaccine 2006; 24(25): 5311–9.
Jiang Z, et al. Remission of CVB3-induced viral myocarditis by in vivo Th2 polarization via hydrodynamics-based interleukin-4 gene transfer. J Gene Med 2008; 10: 918–29.
Jimenez C, et al. Graves’ disease after interleukin-2 therapy in a patient with human immunodeficiency virus infection. Thyroid 2004; 14: 1097–102.
Johnson BJ, et al. rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: A comparison of two treatment regimens and placebo. Tuberc Lung Dis 1997; 78: 195–203.
Johnson BJ, et al. Clinical and immune responses of tuberculosis patients treated with low-dose IL-2 and multidrug therapy. Cytokin Molec Ther 1995; 1: 185–96.
Johnson JL, et al. Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis [Comment]. Am J Respir Crit Care Med 2003; 168: 185–91.
Jones CE, et al. Inosiplex therapy in subacute sclerosing panencephalitis. A multicentre, non-randomised study in 98 patients. Lancet 1982; 1: 1034–7.
Kaiser K, et al. Recombinant human erythropoietin prevents the death of mice during cerebral malaria. J Infect Dis 2006; 193: 987–95.
Kalil AC, et al. Use of interferon-alpha in patients with West Nile encephalitis: Report of 2 cases. Clin Infect Dis 2005; 40: 764–6.
Kamei S, et al. Evaluation of combination therapy using aciclovir and corticosteroid in adult patients with herpes simplex virus encephalitis. J Neurol Neurosurg Psychiatry 2005; 76: 1544–9.
Kamijo R, et al. Mice that lack the interferon-gamma receptor have profoundly altered responses to infection with bacillus Calmette–Guerin and subsequent challenge with lipopolysaccharide. J Exp Med 1993; 178: 1435–40.
Kanra GY, et al. Beneficial effects of dexamethasone in children with pneumococcal meningitis. Pediatr Infect Dis J 1995; 14: 490–4.
Kasper LH, et al. IL-7 stimulates protective immunity in mice against the intracellular pathogen, Toxoplasma gondii. J Immunol 1995; 155: 4798–804.
Kawada J, et al. Systemic cytokine responses in patients with influenza-associated encephalopathy. J Infect Dis 2003; 188: 690–8.
Kawakami K, et al. Il-18 protects mice against pulmonary and disseminated infection with Cryptococcus neoformans by inducing IFN-gamma production. J Immunol 1997; 159: 5528–34.
Kawakami K, et al. Interleukin-4 weakens host resistance to pulmonary and disseminated cryptococcal infection caused by combined treatment with interferon-gamma-inducing cytokines. Cell Immunol 1999; 197: 55–61.
Kawakami K, et al. Reduced host resistance and Th1 response to Cryptococcus neoformans in interleukin-18 deficient mice. FEMS Microbiol Lett 2000; 186: 121–6.
Khan AA, et al. Activity of gatifloxacin alone or in combination with pyrimethamine or gamma interferon against Toxoplasma gondii. Antimicrob Agents Chemother 2001; 45: 48–51.
Khan IA, Kasper L. IL-15 augments CD8+ T cell-mediated immunity against Toxoplasma gondii infection in mice. J Immunol 1996; 157: 2103–8.
Kim D, et al. Relationships between IFNgamma, IL-6, corticosterone, and Listeria monocytogenes pathogenesis in BALB/c mice. Cell Immunol 2001; 207: 13–18.
Kindler V, et al. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989; 56: 731–40.
Kioi M, et al. Mechanism of action of interleukin-13 antagonist (IL-13E13K) in cells expressing various types of IL-4R. Cell Immunol 2004; 229: 41–51.
Kleinschek MA, et al. IL-23 enhances the inflammatory cell response in Cryptococcus neoformans infection and induces a cytokine pattern distinct from IL-12. J Immunol 2006; 176: 1098–106.
Koedel U, et al. Pharmacologic interference with NF-kappaB activation attenuates central nervous system complications in experimental pneumococcal meningitis. J Infect Dis 2000; 182: 1437–45.
Koh WJ, et al. Six-month therapy with aerosolized interferon-gamma for refractory multidrug-resistant pulmonary tuberculosis. J Korean Med Sci 2004; 19: 167–71.
Komatsu T, et al. Neuronal expression of NOS-1 is required for host recovery from viral encephalitis. Virology 1999a; 258: 389–95.
Komatsu T, et al. Regulation of the BBB during viral encephalitis: Roles of IL-12 and NOS. Nitric Oxide 1999b; 3: 327–39.
Kreymborg K, et al. IL-23: changing the verdict on IL-12 function in inflammation and autoimmunity. Expert Opin Ther Targets 2005; 9: 1123–36.
Krown S. Interferons and interferon inducers in cancer treatment. Semin Oncol 1986; 13: 207–17.
Kuipers HF, et al. Simvastatin affects cell motility and actin cytoskeleton distribution of microglia. Glia 2006; 53: 115–23.
Kunschner L, Scott. T. Sustained recovery of progressive multifocal leukoencephalopathy after treatment with IL-2. Neurology 2005; 65: 1510.
Larsen MW, et al. Ginseng modulates the immune response by induction of interleukin-12 production. APMIS 2004; 112: 369–73.
Lauterbach H, et al. Adoptive immunotherapy induces CNS dendritic cell recruitment and antigen presentation during clearance of a persistent viral infection. J Exp Med 2006; 203: 1963–75.
Lebel MH, et al. Dexamethasone therapy for bacterial meningitis. Results of two double-blind, placebo-controlled trials. N Engl J Med 1988; 319: 964–71.
Lee JD, et al. Interleukin-4 inhibits the expression of tumour necrosis factors α and β, interleukins-1β and -6 and interferon-γ. Immunol Cell Biol 1995; 73: 57–61.
Leib SL, et al. Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis. Infect Immun 2000; 68: 615–20.
Lieberman LA, et al. IL-23 provides a limited mechanism of resistance to acute toxoplasmosis in the absence of IL-12. J Immunol 2004; 173: 1887–93.
Lieschke GJ, et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 1994; 84: 1737–46.
Little RF, et al. Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. Blood 2006; 107: 4650–7.
Long MT, Baszler TV. Neutralization of maternal IL-4 modulates congenital protozoal transmission: Comparison of innate versus acquired immune responses. J Immunol 2000; 164: 4768–74.
Looareesuwan S, et al. Pentoxifylline as an ancillary treatment for severe falciparum malaria in Thailand. Am J Trop Med Hyg 1998; 58: 348–53.
Lortholary O, et al. Immune mediators in cerebrospinal fluid during cryptococcosis are influenced by meningeal involvement and human immunodeficiency virus serostatus. J Infect Dis 2001; 183: 294–302.
Lotze M, et al. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 1986; 58: 2764–72.
Luft BJ, et al. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1993; 329: 995–1000.
Mannon PJ, et al. Anti-interleukin-12 antibody for active Crohn’s disease. N Engl J Med 2004; 351: 2069–79.
Maret A, et al. Estradiol enhances primary antigen-specific CD4 T cell responses and Th1 development in vivo. Essential role of estrogen receptor alpha expression in hematopoietic cells. Eur J Immunol 2003; 33: 512–21.
Matejuk A, et al. 17 beta-estradiol inhibits cytokine, chemokine, and chemokine receptor mRNA expression in the central nervous system of female mice with experimental autoimmune encephalomyelitis. J Neurosci Res 2001; 65: 529–42.
McArthur JC, et al. Steroid-responsive myeloneuropathy in a man dually infected with HIV-1 and HTLV-I. Neurology 1990; 40: 938–44.
Medana IM, et al. Central nervous system in cerebral malaria: “Innocent bystander” or active participant in the induction of immunopathology? [Review]. Immunol Cell Biol 2001; 79: 101–20.
Merigan T, et al. Human leukocyte interferon for the treatment of Herpes Zoster in patients with cancer. N Engl J Med 1978; 298: 981–7.
Meydani SN, et al. Vitamin E supplementation and in vivo immune response in healthy elderly subjects. A randomized controlled trial. J Am Med Assoc 1997; 277: 1380–6.
Miller A, et al. Cimetidine as an immunomodulator in the treatment of herpes zoster. J Neuroimmunol 1989; 22: 69–76.
Miyazaki M, et al. Long-term follow-up of a patient with subacute sclerosing panencephalitis successfully treated with intrathecal interferon alpha. Brain Dev 2005; 27: 301–3.
Molavi A, Le Frock J. Tuberculous meningitis. Med Clin North Am 1985; 69: 315–31.
Molyneux EM, et al. Dexamethasone treatment in childhood bacterial meningitis in Malawi: A randomised controlled trial. Lancet 2002; 360: 211–18.
Morales LB, et al. Treatment with an estrogen receptor alpha ligand is neuroprotective in experimental autoimmune encephalomyelitis. J Neurosci 2006; 26: 6823–33.
Mori I, et al. Impaired microglial activation in the brain of IL-18-gene-disrupted mice after neurovirulent influenza A virus infection. Virology 2001; 287: 163–70.
Moro MH, et al. Gestational attenuation of Lyme arthritis is mediated by progesterone and IL-4. J Immunol 2001; 166: 7404–9.
Mukherjee S, et al. Dendritic cells infected with a vaccinia virus interleukin-2 vector secrete high levels of IL-2 and can become efficient antigen presenting cells that secrete high levels of the immunostimulatory cytokine IL-12. Cancer Gene Therapy 2003; 10(8): 591–602.
Murray H. Interferon-gamma, the activated macrophage and host defence against microbial challenge. Ann Intern Med 1988; 108: 595–608.
Murray H, et al. Impaired production of lymphokines and immune (gamma) interferon in the acquired immunodeficiency syndrome. N Engl J Med 1984; 310: 883.
Murray HW, et al. In vitro and in vivo activation of human mononuclear phagocytes by interferon-gamma. Studies with normal and AIDS monocytes. J Immunol 1987; 138: 2457–62.
Mustafa M, et al. Role of tumor necrosis factor alpha (cachectin) in experimental and clinical bacterial meningitis. Pediatr Infect Dis J 1989; 8: 907–8.
Nakane A, et al. Protection by dexamethasone from a lethal infection with Listeria monocytogenes in mice. FEMS Immunol Med Microbiol 1994; 9: 163–70.
Nakane A, et al. Endogenous cytokines during a lethal infection with Listeria monocytogenes in mice. FEMS Microbiol Lett 1999; 175: 133–42.
Nakano T, et al. Recurrent herpes zoster myelitis treated with human interferon alpha: A case report. Acta Neurol Scand 1992; 85: 372–5.
Nash TE. Human case management and treatment of cysticercosis. Acta Trop 2003; 87: 61–9.
Nath A, et al. Progression of progressive multifocal leukoencephalopathy despite treatment with beta-interferon. Neurology 2006; 66: 149–50.
Newton C, et al. Induction of interleukin-4 (IL-4) by Legionella pneumophila infection in BALB/c mice and regulation of tumor necrosis factor alpha, IL-6, and IL-1 beta. Infect Immun 2000; 68: 5234–40.
Neyer LE, et al. Role of interleukin-10 in regulation of T-cell-dependent and T-cell-independent mechanisms of resistance to Toxoplasma gondii. Infect Immun 1997; 65: 1675–82.
Noisakran S, et al. IFN-alpha 1 plasmid construct affords protection against HSV-1 infection in transfected L929 fibroblasts. J Interfer Cytokin Res 2000; 20: 107–15.
Novelli F, Casanova J. The role of IL-12, IL-23 and IFN-gamma in immunity to viruses. Cytokine Growth Factor Rev 2004; 15: 367–77.
Odio CM, et al. The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis. N Engl J Med 1991; 324: 1525–31.
Ohga S, et al. Cerebrospinal fluid cytokine levels and dexamethasone therapy in bacterial meningitis. J Infect 1999; 39: 55–60.
Okamura H, et al. Interleukin-18: A novel cytokine that augments both innate and acquired immunity. Adv Immunol 1998; 70: 281–312.
Opal SM, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997; 25: 1115–24.
Operschall E, et al. Enhanced protection against viral infection by co-administration of plasmid DNA coding for viral antigen and cytokines in mice. J Clin Virol 1999; 13: 17–27.
Orange JS, et al. Mechanism of interleukin 12-mediated toxicities during experimental viral infections: Role of tumor necrosis factor and glucocorticoids. J Exp Med 1995; 181: 901–14.
Osorio Y, Ghiasi H. Comparison of adjuvant efficacy of herpes simplex virus type 1 recombinant viruses expressing TH1 and TH2 cytokine genes. J Virol 2003; 77: 5774–83.
Osorio Y, Ghiasi H. Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocularHSV-1 challenge. J Virol 2005; 79: 3297–308.
Osorio Y, et al. The role of T(H)1 and T(H)2 cytokines in HSV-1-induced corneal scarring. Ocul Immunol Inflamm 2002; 10: 105–16.
Ozato K, et al. Toll-like receptor signaling and regulation of cytokine gene expression in the immune system [Review]. Biotechniques 2002; Suppl S: 66.
Pachner AR, et al. Interleukin-6 is expressed at high levels in the CNS in Lyme neuroborreliosis. Neurology 1997; 49: 147–52.
Padgett DA, Sheridan JF. Androstenediol (AED) prevents neuroendocrine-mediated suppression of the immune response to an influenza viral infection. J Neuroimmunol 1999; 98: 121–9.
Palmero D, et al. Phase II trial of recombinant interferon-alpha2b in patients with advanced intractable multidrug-resistant pulmonary tuberculosis: Long-term follow-up. Int J Tuberc Lung Dis 1999; 3: 214–18.
Panitch HS, et al. Subacute sclerosing panencephalitis: Remission after treatment with intraventricular interferon. Neurology 1986; 36: 562–6.
Paris MM, et al. Effect of interleukin-1 receptor antagonist and soluble tumor necrosis factor receptor in animal models of infection. J Infect Dis 1995; 171: 161–9.
Paris MM, et al. The effect of interleukin-10 on meningeal inflammation in experimental bacterial meningitis. J Infect Dis 1997; 176: 1239–46.
Park MH, et al. ERK-mediated production of neurotrophic factors by astrocytes promotes neuronal stem cell differentiation by erythropoietin. Biochem Biophys Res Commun 2006; 339: 1021–8.
Pietrella D, et al. Disruption of CD40/CD40L interaction influences the course of Cryptococcus neoformans infection. FEMS Immunol Med Microbiol 2004; 40: 63–70.
Polanczyk M, et al. The protective effect of 17beta-estradiol on experimental autoimmune encephalomyelitis is mediated through estrogen receptor-alpha. Am J Pathol 2003; 163: 1599–605.
Prasad K, Garner P. Steroids for treating cerebral malaria. Cochrane Database Syst Rev 2000; 2: CD000972.
Rahal JJ, et al. Effect of interferon-alpha2b therapy on St. Louis viral meningoencephalitis: Clinical and laboratory results of a pilot study. J Infect Dis 2004; 190: 1084–7.
Rasley A, et al. Murine glia express the immunosuppressive cytokine, interleukin-10, following exposure to Borrelia burgdorferi or Neisseria meningitidis. Glia 2006; 53: 583–92.
Reddy AM, et al. Artemisolide from Artemisia asiatica: Nuclear factor-kappaB (NF-kappaB) inhibitor suppressing prostaglandin E2 and nitric oxide production in macrophages. Arch Pharm Res 2006; 29: 591–7.
Roberts CW, et al. Different roles for interleukin-4 during the course of Toxoplasma gondii infection. Infect Immun 1996; 64: 897–904.
Rock RB, et al. Mycobacterium tuberculosis-induced cytokine and chemokine expression by human microglia and astrocytes: Effects of dexamethasone. J Infect Dis 2005; 192: 2054–8.
Rodrigues V, et al. Interleukin-5 and interleukin-10 are major cytokines in cerebrospinal fluid from patients with active neurocysticercosis. Brazil J Med Biolog Res 2000; 33: 1059–63.
Rodriguez FH, et al. Cytokine therapeutics for infectious diseases [Review]. Curr Pharmaceut Des 2000; 6: 665–80.
Rosenberg SA, et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother 2006; 29: 313–19.
Roy E, et al. Beneficial effect of anti-interleukin-4 antibody when administered in a murine model of tuberculosis infection. Tuberculosis 2008; 88: 197–202.
Ryman KD, et al. Alpha/beta interferon protects adult mice from fatal Sindbis virus infection and is an important determinant of cell and tissue tropism. J Virol 2000; 74: 3366–78.
Saez-Llorens X, et al. Molecular pathophysiology of bacterial meningitis: current concepts and therapeutic implications. J Pediatr 1990a; 116: 671–84.
Saez-Llorens X, et al. Pentoxifylline modulates meningeal inflammation in experimental bacterial meningitis. Antimicrob Agents Chemother 1990b; 34: 837–43.
Sangro B, et al. Gene therapy of cancer based on interleukin 12. Curr Gene Ther 2005; 5: 573–81.
Sayao AL, et al. Calgary experience with West Nile virus neurological syndrome during the late summer of 2003. Can J Neurol Sci 2004; 31: 194–203.
Schaad UB, et al. Dexamethasone therapy for bacterial meningitis in children. Swiss Meningitis Study Group. Lancet 1993; 342: 457–61.
Schaefer C, et al. Gene-based delivery of IFN-beta is efficacious in a murine model of experimental allergic encephalomyelitis. J Interferon Cytokine Res 2006; 26: 449–54.
Scharton-Kersten T, et al. Role of IL12 in induction of cell-mediated immunity to Toxoplasma gondii Res Immunol 1995; 146: 539–45. [Erratum appears in Res Immunol 1996; 147(2): 121.]
Schauf V, et al. Cytokine gene activation and modified responsiveness to interleukin-2 in the blood of tuberculosis patients. J Infect Dis 1993; 168: 1056–9.
Schluter D, et al. Regulation of microglia by CD4+ and CD8+ T cells: Selective analysis in CD45-congenic normal and Toxoplasma gondii-infected bone marrow chimeras. Brain Pathol 2001; 11: 44–55.
Schoeman JF, et al. Intractable intracranial tuberculous infection responsive to thalidomide: Report of four cases. J Child Neurol 2006; 21: 301–8.
Schoeman JF, et al. Adjunctive thalidomide therapy for childhood tuberculous meningitis: Results of a randomized study. J Child Neurol 2004; 19: 250–7.
Sharma SD, et al. In vivo recombinant interleukin 2 administration enhances survival against a lethal challenge with Toxoplasma gondii. J Immunol 1985; 135: 4160–3.
Simmons CP, et al. The clinical benefit of adjunctive dexamethasone in tuberculous meningitis is not associated with measurable attenuation of peripheral or local immune responses. J Immunol 2005; 175: 579–90.
Simmons CP, et al. Pretreatment intracerebral and peripheral blood immune responses in Vietnamese adults with tuberculous meningitis: Diagnostic value and relationship to disease severity and outcome. J Immunol 2006; 176: 2007–14.
Smolen JS, Maini. R. Interleukin-6: A new therapeutic target. Arthritis Res Ther 2006; 8(S2): S5.
Solomon T, et al. Interferon alfa-2a in Japanese encephalitis: A randomised double-blind placebo-controlled trial. Lancet 2003; 361: 821–6.
Steiger MJ, et al. Successful outcome of progressive multifocal leukoencephalopathy with cytarabine and interferon. Ann Neurol 1993; 33: 407–11.
Stumhofer JS, et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol 2006; 7: 937–45.
Subauste CS, et al. CD40–CD40 ligand interaction is central to cell-mediated immunity against Toxoplasma gondii: Patients with hyper IgM syndrome have a defective type 1 immune response that can be restored by soluble CP40 ligand trimer. J Immunol 1999; 162: 6690–700.
Sugawara I. Interleukin-18 (IL-18) and infectious diseases, with special emphasis on diseases induced by intracellular pathogens [Review]. Microb Infect 2000; 2: 1257–63.
Sugawara I, et al. IL-4 is required for defense against mycobacterial infection. Microbiol Immunol 2000; 44: 971–9.
Suzuki Y, et al. Importance of endogenous IFN-γ for prevention of toxoplasmic encephalitis in mice. J Immunol 1989; 143: 2045–50.
Suzuki Y, et al. Treatment of toxoplasmic encephalitis in mice with recombinant gamma interferon. Infect Immun 1990; 58: 3050–5.
Suzuki Y, Yang Q. IL-4 is protective against development of toxoplasmic encephalitis. J Immunol 1996; 157: 2564–9.
Suzuki Y, et al. Impaired resistance to the development of toxoplasmic encephalitis in interleukin-6-deficient mice. Infect Immun 1997; 65: 2339–45.
Szalay G, et al. IL-4 neutralization or TNF-alpha treatment ameliorate disease by an intracellular pathogen in IFN-gamma receptor-deficient mice. J Immunol 1996; 157: 4746–50.
Takayanagui OM, Jardim E. Therapy for neurocysticercosis. Comparison between albendazole and praziquantel. Arch Neurol 1992; 49: 290–4.
Tan J, et al. Activation of microglial cells by the CD40 pathway: relevance to multiple sclerosis. J Neuroimmunol 1999; 97: 77–85.
Teige I, et al. IFN-beta inhibits T cell activation capacity of central nervous system APCs. J Immunol 2006; 177: 3542–53.
Teppler H, et al. Efficacy of low doses of the polyethylene glycol derivative of interleukin-2 in modulating the immune response of patients with human immunodeficiency virus type 1 infection. J Infect Dis 1993; 167: 291–8.
Thomas R, et al. Trial of dexamethasone treatment for severe bacterial meningitis in adults. Intens Care Med 1999; 25: 475–80.
Thwaites GE, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004; 351: 1741–51.
Tischner D, et al. Antigen therapy of experimental autoimmune encephalomyelitis selectively induces apoptosis of pathogenic T cells. J Neuroimmunol 2006; 183: 146–50.
Todd P, Goa K. Interferon gamma-1b. A review of its pharmacology and therapeutic potential in chronic granulomatous disease. Drugs 1992; 43: 111–22.
Tsai ML, et al. Cerebrospinal fluid interleukin-6, interleukin-8, and tumor necrosis factor-alpha in children with central nervous system infections. Acta Paediatr Sin 1996; 37: 16–21.
Tsao TC, et al. Imbalances between tumor necrosis factor-alpha and its soluble receptor forms, and interleukin-1 beta and interleukin-1 receptor antagonist in BAL fluid of cavitary pulmonary tuberculosis. Chest 2000; 117: 103–9.
Tsenova L, et al. Tumor necrosis factor alpha is a determinant of pathogenesis and disease progression in mycobacterial infection in the central nervous system. Proc Natl Acad Sci 1999; 96: 5657–62.
Tsenova L, et al. A combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death. J Infect Dis 1998; 177: 1563–72.
Tsoukas CD, et al. 1,25-dihydroxyvitamin D3: A novel immunoregulatory hormone. Science 1984; 224: 1438–40.
Tucker PC, et al. Inhibition of nitric oxide synthesis increases mortality in Sindbis virus encephalitis. J Virol 1996; 70: 3972–7.
Turowski P, et al. Pharmacological targeting of ICAM-1 signaling in brain endothelial cells: Potential for treating neuroinflammation. Cell Mol Neurobiol 2005; 25: 153–70.
Ulrichs T, et al. Variable outcome of experimental interferon-gamma therapy of disseminated Bacillus Calmette–Guerin infection in two unrelated interleukin-12Rbeta1-deficient Slovakian children. Eur J Pediatr 2005; 164: 166–72.
Urban JF, et al. Stat6 signaling promotes protective immunity against Trichinella spiralis through a mast cell- and T cell-dependent mechanism. J Immunol 2000; 164: 2046–52.
Uyttenhove C, Van Snick J. Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis. Eur J Immunol 2006; 36: 2868–74.
Uyttenhove C, et al. Development of an anti-IL-12 p40 auto-vaccine: Protection in experimental autoimmune encephalomyelitis at the expense of increased sensitivity to infection. Eur J Immunol 2004; 34: 3572–81.
van Deuren M, et al. Differential expression of proinflammatory cytokines and their inhibitors during the course of meningococcal infections. J Infect Dis 1994; 169: 157–61.
van Marle G, et al. Human immunodeficiency virus type 1 envelope-mediated neuropathogenesis: Targeted gene delivery by a Sindbis virus expression vector. Virology 2003; 309(1): 61–74.
Vento S, et al. Interleukin-2 therapy and CD4+ T cells in HIV-1 infection. Lancet 2006; 367: 93–5.
Villegas EN, et al. Susceptibility of interleukin-2-deficient mice to Toxoplasma gondii is associated with a defect in the production of gamma interferon. Infect Immun 2002; 70: 4757–61.
von der Wense A, et al. Intrathecal interferon therapy in chronic echovirus meningoencephalitis in Bruton type agammaglobulinemia. Klin Padiatr 1998; 210: 51–5 [in German].
von Giesen HJ, et al. Serum and cerebrospinal fluid levels of interleukin-18 in human immunodeficiency virus type 1-associated central nervous system disease. J Neurovirol 2004; 10: 383–6.
Wagner RD, et al. Recombinant interleukin-12 enhances resistance of mice to Listeria monocytogenes infection. Microb Pathog 1994; 17: 175–86.
Wald ER, et al. Dexamethasone therapy for children with bacterial meningitis. Meningitis Study Group. Pediatrics 1995; 95: 21–8.
Wallis RS, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38: 1261–5.
Wang ZW, et al. Attenuated rabies virus activates, while pathogenic rabies virus evades, the host innate immune responses in the central nervous system. J Virol 2005; 79: 12554–65.
Warrell MJ, et al. Failure of interferon alfa and tribavirin in rabies encephalitis. Br Med J 1989; 299: 830–3.
Wassie L, et al. Ex vivo cytokine mRNA levels correlate with changing clinical status of Ethiopian TB patients and their contacts over time. PLoS ONE 2008; 3: e1522.
Wenisch C, et al. Elevated serum levels of IL-10 and IFN-gamma in patients with acute Plasmodium falciparum malaria. Clin Immunol Immunopathol 1995; 74: 115–7.
Wenisch C, et al. Effect of pentoxifylline on cytokine patterns in the therapy of complicated Plasmodium falciparum malaria. Am J Trop Med Hyg 1998; 58: 343–7.
Wingerchuk D. Current evidence and therapeutic strategies for multiple sclerosis. Semin Neurol 2008; 28: 56–68.
Winston D, et al. Recombinant interferon-alpha-2a for treatment of Herpes Zoster in immunocompromised patients with cancer. Am J Med 1988; 85: 147–51.
Wintergerst U, Behlohradsky B. Acyclovir versus acyclovir plus beta-interferon in focal viral encephalitis in children. Infection 1992; 20: 207–12.
Wintergerst U, et al. Therapy of focal viral encephalitis in children with aciclovir and recombinant beta-interferon – results of a placebo-controlled multicenter study. Eur J Med Res 2005; 10: 527–31.
Wu DT, et al. Mechanisms of leukocyte trafficking into the CNS. J Neurovirol 2000; 6(Suppl 1): S82–5.
Xue ML, et al. 1 Alpha,25-Dihydroxyvitamin D-3 inhibits pro-inflammatory cytokine and chemokine expression in human corneal epithelial cells colonized with Pseudomonas aeruginosa. Immunol Cell Biol 2002; 80: 340–5.
Yamanaka R, Xanthopoulos K. Induction of antigen-specific immune responses against malignant brain tumors by intramuscular injection of sindbis DNA encoding gp100 and IL-18. DNA Cell Biol 2005; 24: 317–24.
Yamanaka R, et al. Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12. J Neurosurg 2002; 97: 611–18.
Yamasaki K, et al. Long-term, high dose interferon-alpha treatment in HTLV-I-associated myelopathy/tropical spastic paraparesis: A combined clinical, virological and immunological study. J Neurol Sci 1997; 147: 135–44.
Yoshioka H, et al. Administration of human leukocyte interferon to patients with subacute sclerosing panencephalitis. Brain Dev 1989; 11: 302–7.
Zeinstra E, et al. Simvastatin inhibits interferon-gamma-induced MHC class II up-regulation in cultured astrocytes. J Neuroinflam 2006; 3: 16.
Zeuzem S, et al. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C. Hepatology 1999; 29: 1280–7.
Zhu Y, et al. Lentivirus infection causes neuroinflammation and neuronal injury in dorsal root ganglia: Pathogenic effects of STAT-1 and inducible nitric oxide synthase. J Immunol 2005; 175: 1118–26.
Zwijnenburg PJG, et al. Interleukin-18 gene-deficient mice show enhanced defense and reduced inflammation during pneumococcal meningitis. J Neuroimmunol 2003; 138: 31–7.

References

Aisen PS, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. J Am Med Assoc 2003; 289: 2819–26.
Alder J, et al. Interferon-gamma dose-dependently inhibits prostaglandin E2-mediated dendritic-cell-migration towards secondary lymphoid organ chemokines. Vaccine 2006; 24: 7087–94.
Balatoni B, et al. FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res Bull 2007; 74: 307–16.
Bartt RE. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy. Curr Opin Neurol 2006; 19: 341–9.
Bechtold DA, et al. Axonal protection achieved in a model of multiple sclerosis using lamotrigine. J Neurol 2006; 253:1542–51.
Bielekova B, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000; 6: 1167–75.
Bielekova B, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci USA 2004; 101: 8705–8.
Black JA, et al. Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine. Ann Neurol 2007; 62: 21–33.
Bredesen DE, et al. Cell death in the nervous system. Nature 2006; 443: 796–802.
Brendza RP, Holtzman DM. Amyloid-beta immunotherapies in mice and men. Alzheimer Dis Assoc Disord 2006; 20: 118–23.
Brocke S, et al. Antibodies to CD44 and integrin alpha4, but not l-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. Proc Natl Acad Sci USA 1999; 96: 6896–901.
Buch T, Waisman A. Protection from autoimmunity by DNA vaccination against T-cell receptor. Meth Mol Med 2006; 127: 269–80.
Calabresi PA, et al. An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS. Neurology 2002; 58: 314–17.
Callahan MK, Ransohoff RM. Analysis of leukocyte extravasation across the blood–brain barrier: Conceptual and technical aspects. Curr Allergy Asthma Rep 2004; 4: 65–73.
Carri MT, et al. Targets in ALS: designing multidrug therapies. Trends Pharmacol Sci 2006; 27: 267–73.
Cavaletti G. Current status and future prospective of immunointervention in multiple sclerosis. Curr Med Chem 2006;13: 2329–43.
Chavarria A, Alcocer-Varela J. Is damage in central nervous system due to inflammation? Autoimmun Rev 2004; 3: 251–60.
Coles AJ, et al. Alemtuzumab vs. Interferon Beta-1a in early multiple sclerosis. N Engl J Med 2008; 359: 1786–801.
Confavreux C, Moreau T. Emerging treatments in multiple sclerosis: Azathioprine and mofetil. Mult Scler 1996; 1: 379–84.
Cosentino M, et al. Interferon-gamma and interferon-beta affect endogenous catecholamines in human peripheral blood mononuclear cells: Implications for multiple sclerosis. J Neuroimmunol 2005; 162: 112–21.
Creput C, et al. New therapeutic targets for antibodies and recombinant proteins in organ transplantation. Curr Opin Mol Ther 2007; 9: 153–9.
Cross AH, et al. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 2006; 180: 63–70.
Cysique LA, et al. Valproic acid is associated with cognitive decline in HIV-infected individuals: A clinical observational study. BMC Neurol 2006; 6: 42.
Defeudis FV. Bilobalide and neuroprotection. Pharmacol Res 2002; 46: 565–8.
Dou H, et al. Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis. J Neurosci 2003; 23: 9162–70.
Dyke HJ, Montana JG. Update on the therapeutic potential of PDE4 inhibitors. Expert Opin Investig Drugs 2002; 11: 1–13.
Edling AE, et al. An organic CD4 inhibitor reduces the clinical and pathological symptoms of acute experimental allergic encephalomyelitis. J Autoimmun 2002; 18: 169–79.
Emerich DF, Thanos CG. Intracompartmental delivery of CNTF as therapy for Huntington’s disease and retinitis pigmentosa. Curr Gene Ther 2006; 6: 147–59.
Fernandez-Martin A, et al. VIP prevents experimental multiple sclerosis by downregulating both inflammatory and autoimmune components of the disease. Ann NY Acad Sci 2006; 1070: 276–81.
Fox EJ. Management of worsening multiple sclerosis with mitoxantrone: A review. Clin Ther 2006; 28: 461–74.
Frank B, Gupta S. A review of antioxidants and Alzheimer’s disease. Ann Clin Psychiatry 2005; 17: 269–86.
Gerdes JM, Katsanis N. Small molecule intervention in microtubule-associated human disease. Hum Mol Genet 2005; 14 Spec No. 2: R291–300.
Gray OM, et al. A systematic review of oral methotrexate for multiple sclerosis. Mult Scler 2006; 12: 507–10.
Griffin DE. Immune responses to RNA-virus infections of the CNS. Nat Rev Immunol 2003; 3: 493–502.
Hauser SL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676–88.
Henderson VW. Estrogen-containing hormone therapy and Alzheimer’s disease risk: understanding discrepant inferences from observational and experimental research. Neuroscience 2006; 138: 1031–9.
Huang HM, et al. Amyloid beta peptide impaired carbachol but not glutamate-mediated phosphoinositide pathways in cultured rat cortical neurons. Neurochem Res 2000; 25: 303–12.
Johnson KP, Panitch HS. Effects of experimental recombinant interferons on multiple sclerosis. Trans Am Clin Climatol Assoc 1988; 100: 171–6.
Johnson RT. Viral Infections of the Nervous System. 2nd edn (ed. Mark Placito EH). Philadelphia: Lippincott-Raven Publishers, 1998; 265–314.
Johnston JB, et al. HIV-1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors. Ann Neurol 2001; 49: 230–41.
Kang BS, et al. Oral administration of live virus protects susceptible mice from developing Theiler’s virus-induced demyelinating disease. Virology 2007; 366: 185–96.
Kaur C, et al. Origin of microglia. Microsc Res Tech 2001; 54: 2–9.
Kelly M, et al. Modulating leukocyte recruitment in inflammation. J Allergy Clin Immunol 2007; 120: 3–10.
Kerfoot SM, Kubes P. Overlapping roles of P-selectin and alpha 4 integrin to recruit leukocytes to the central nervous system in experimental autoimmune encephalomyelitis. J Immunol 2002; 169: 1000–6.
Kilic E, et al. TAT-GDNF in neurodegeneration and ischemic stroke. CNS Drug Rev 2005; 11: 369–78.
Kosugi I, et al. Innate immune responses to cytomegalovirus infection in the developing mouse brain and their evasion by virus-infected neurons. Am J Pathol 2002; 161: 919–28.
Langer-Gould A, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353: 375–81.
Lapointe BM, et al. IVIg therapy in brain inflammation: etiology-dependent differential effects on leucocyte recruitment. Brain 2004; 127: 2649–56.
Lee CZ, et al. Doxycycline suppresses cerebral matrix metalloproteinase-9 and angiogenesis induced by focal hyperstimulation of vascular endothelial growth factor in a mouse model. Stroke 2004; 35: 1715–9.
Leist TP, Vermersch P. The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation. Curr Med Res Opin 2007; 23: 2667–76.
Loewe R, et al. Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells. J Immunol 2002; 168: 4781–7.
Lovett-Racke AE, et al. Silencing T-bet defines a critical role in the differentiation of autoreactive T lymphocytes. Immunity 2004; 21: 719–31.
Lowenstein PR. Immunology of viral-vector-mediated gene transfer into the brain: An evolutionary and developmental perspective. Trends Immunol 2002; 23: 23–30.
Lucas SM, et al. The role of inflammation in CNS injury and disease. Br J Pharmacol 2006; 147 (Suppl 1): S232–40.
Maehlen J, et al. Axotomy induces MHC class I antigen expression on rat nerve cells. Neurosci Lett 1988; 92: 8–13.
Martinez-Rodriguez JE, et al. Cladribine in aggressive forms of multiple sclerosis. Eur J Neurol 2007; 14(6): 686–9.
Matney SE, Huff DR. Diagnosis and treatment of myasthenia gravis. Consult Pharm 2007; 22: 239–48.
Medyouf H, et al. Targeting calcineurin activation as a therapeutic strategy for T-cell acute lymphoblastic leukemia. Nat Med 2007; 13: 736–41.
Morrissey SP, et al. Mitoxantrone in the treatment of multiple sclerosis. Int MS J 2005; 12(3): 74–87.
Mueller BK, et al. Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov 2005; 4: 387–98.
Nash PT, Florin TH. Tumour necrosis factor inhibitors. Med J Aust 2005; 183: 205–8.
Neumann H. Control of glial immune function by neurons. Glia 2001; 36: 191–9.
Neumann H, et al. Major histocompatibility complex (MHC) class I gene expression in single neurons of the central nervous system: differential regulation by interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha. J Exp Med 1997; 185: 305–16.
O’Connor PW, et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006; 66: 894–900.
Orgogozo JM, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003; 61: 46–54.
Paintlia AS, et al. Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitis. Am J Pathol 2006; 169: 1012–25.
Piraino PS, et al. Suppression of acute experimental allergic encephalomyelitis with a small molecule inhibitor of alpha4 integrin. Mult Scler 2005; 11: 683–90.
Polman C, et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005; 64: 987–91.
Pozzi S, et al. Estrogen action in neuroprotection and brain inflammation. Ann NY Acad Sci 2006; 1089: 302–23.
Prinz M, et al. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 2008; 28: 675–86.
Ransohoff RM, et al. Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 2003; 3: 569–81.
Reddy DS. Role of neurosteroids in catamenial epilepsy. Epilepsy Res 2004; 62: 99–118.
Reijerkerk A, et al. Diapedesis of monocytes is associated with MMP-mediated occludin disappearance in brain endothelial cells. FASEB J 2006; 20: 2550–2.
Ringshausen I, et al. The immunomodulatory drug Leflunomide inhibits cell cycle progression of B-CLL cells. Leukemia 2008; 22: 635–8.
Rogers J, et al. Neuroinflammation in Alzheimer’s disease and Parkinson’s disease: Are microglia pathogenic in either disorder? Int Rev Neurobiol 2007; 82: 235–46.
Roney C, et al. Targeted nanoparticles for drug delivery through the blood–brain barrier for Alzheimer’s disease. J Control Release 2005; 108: 193–214.
Ropper AH. Selective treatment of multiple sclerosis. N Engl J Med 2006; 354: 965–7.
Ruffini F, et al. Fibroblast growth factor-II gene therapy reverts the clinical course and the pathological signs of chronic experimental autoimmune encephalomyelitis in C57BL/6 mice. Gene Ther 2001; 8: 1207–13.
Runstrom A, et al. Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice. J Neuroimmunol 2006; 173: 69–78.
Salama B, et al. Optic neuropathy in refractory neurosarcoidosis treated with TNF-alpha antagonist. Can J Ophthalmol 2006; 41: 766–8.
Schifitto G, et al. Valproic acid adjunctive therapy for HIV-associated cognitive impairment: A first report. Neurology 2006; 66: 919–21.
Schimrigk S, et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol 2006; 13: 604–10.
Schwartz M, Kipnis J. Protective autoimmunity and neuroprotection in inflammatory and noninflammatory neurodegenerative diseases. J Neurol Sci 2005; 233: 163–6.
Scott LJ, Figgitt DP. Mitoxantrone: A review of its use in multiple sclerosis. CNS Drugs 2004; 18: 379–96.
Shytle RD, et al. Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. J Neurochem 2004; 89: 337–43.
Steinman L. Elaborate interactions between the immune and nervous systems. Nature Immunol 2004; 5: 575–81.
Stepkowski SM. Molecular targets for existing and novel immunosuppressive drugs. Expert Rev Mol Med 2000; 2: 1–23.
Stuve O, et al. Statins as potential therapeutic agents in multiple sclerosis. Curr Neurol Neurosci Rep 2004; 4: 237–44.
Sugiyama K, et al. Comparison of suppressive potency between azathioprine and 6-mercaptopurine against mitogen-induced blastogenesis of human peripheral blood mononuclear cells in-vitro. J Pharm Pharmacol 2003; 55: 393–8.
Teixeira MM, et al. The role of lipocortin-1 in the inhibitory action of dexamethasone on eosinophil trafficking in cutaneous inflammatory reactions in the mouse. Br J Pharmacol 1998; 123: 538–44.
Thatcher GR, et al. NO chimeras as therapeutic agents in Alzheimer’s disease. Curr Alzheimer Res 2006; 3: 237–45.
Treumer F, et al. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol 2003; 121: 1383–8.
Uyttenhove C, Van Snick J. Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis. Eur J Immunol 2006; 36: 2868–74.
Wang C, et al. Antigen-specific therapy promotes repair of myelin and axonal damage in established EAE. J Neurochem 2006; 98: 1817–27.
Warren KG, et al. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: Results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment. Eur J Neurol 2006; 13: 887–95.
Waxman SG. Ions, energy and axonal injury: Towards a molecular neurology of multiple sclerosis. Trends Mol Med 2006; 12: 192–5.
Weber MS, et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nature Med 2007; 13: 935–43.
Woodruff TM, et al. Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. FASEB J 2006; 20: 1407–17.
Xiu J, et al. Expression of nicotinic receptors on primary cultures of rat astrocytes and up-regulation of the alpha7, alpha4 and beta2 subunits in response to nanomolar concentrations of the beta-amyloid peptide(1–42). Neurochem Int 2005; 47: 281–90.
Yang JS, et al. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J Neuroimmunol 2004; 156: 3–9.
Yednock TA, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992; 356: 63–6.
Yong VW. Differential mechanisms of action of interferon-beta and glatiramer acetate in MS. Neurology 2002; 59: 802–8.
Yong VW, et al. Experimental models of neuroprotection relevant to multiple sclerosis. Neurology 2007; 68: pS32–7; discussion S43–54.
Yousry TA, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006; 354: 924–33.
Zheng YQ, et al. Effects of crocin on reperfusion-induced oxidative/nitrative injury to cerebral microvessels after global cerebral ischemia. Brain Res 2007; 1138: 86.